252 related articles for article (PubMed ID: 9815602)
1. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
4. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF).
Osborne CK; Coronado-Heinsohn E
Cancer J Sci Am; 1996; 2(3):175-80. PubMed ID: 9166518
[TBL] [Abstract][Full Text] [Related]
5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
6. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK
Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636
[TBL] [Abstract][Full Text] [Related]
9. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
Simpson BJ; Bartlett JM; Macleod KG; Rabiasz G; Miller EP; Rae AL; Gordge P; Leake RE; Miller WR; Smyth J; Langdon SP
Br J Cancer; 1999 Mar; 79(7-8):1098-103. PubMed ID: 10098742
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
Ye D; Mendelsohn J; Fan Z
Oncogene; 1999 Jan; 18(3):731-8. PubMed ID: 9989823
[TBL] [Abstract][Full Text] [Related]
12. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Bishop PC; Myers T; Robey R; Fry DW; Liu ET; Blagosklonny MV; Bates SE
Oncogene; 2002 Jan; 21(1):119-27. PubMed ID: 11791182
[TBL] [Abstract][Full Text] [Related]
15. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
16. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
[TBL] [Abstract][Full Text] [Related]
17. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
[TBL] [Abstract][Full Text] [Related]
18. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
19. Loss of cytotoxic effect of epidermal growth factor (EGF) on EGF receptor overexpressing cells is associated with attenuation of EGF receptor tyrosine kinase activity.
Gardner DP; Shimizu N
J Cell Physiol; 1994 Feb; 158(2):245-55. PubMed ID: 8106561
[TBL] [Abstract][Full Text] [Related]
20. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]